TRD
Articles tagged with “TRD”
Why Clinicians Are Pushing Harder on TRD Goals
New clinical thinking on treatment-resistant depression pushes toward true remission, not just symptom reduction. Here's what it means for ketamine patients.
Rethinking Treatment-Resistant Depression Care in 2026
New clinical perspectives on treatment-resistant depression push for true remission over symptom reduction. Here's what it means for ketamine patients.
How Clinicians Choose TRD Treatments in 2026
New clinical guidance on treatment-resistant depression highlights how patient preference, speed of response, and functional outcomes shape ketamine treatment decisions.
Esketamine's Role in Treatment-Resistant Depression
A new clinical overview examines esketamine's place in TRD care, including patient selection, access barriers, and rapid-acting benefits for suicidal ideation.
TRD Management: Why Remission Should Be the Goal
New clinical guidance on treatment-resistant depression urges full remission over symptom reduction — here's what it means for low-dose ketamine patients.
Beyond 'Less Bad': Rethinking Treatment-Resistant Depression
Clinicians are pushing beyond symptom reduction in treatment-resistant depression, aiming for full remission. Here's what that means for ketamine patients.
Treatment-Resistant Depression Algorithms: Where Ketamine Fits
Analysis of where ketamine fits within treatment-resistant depression algorithms, reviewing staging models, sequencing strategies, and evidence-based positioning in the TRD pathway.
Low-Dose Ketamine for Treatment-Resistant Depression
An evidence-based overview of low-dose ketamine as a rapidly acting antidepressant for patients with treatment-resistant depression, including mechanisms of action, clinical protocols, and outcome data.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.